MSN: UC, UC Health launching clinical trial to study effectiveness of COVID-19 vaccine
Vaccine uses a genetic code to produce proteins that may generate protective antibodies
UC and UC Health are hosting a Phase 3 clinical trial to evaluate the effectiveness of a vaccine for COVID-19. UC is one of 90 sites across the United States selected for the study, which will administer the vaccine to volunteer participants and monitor its efficacy in eliciting an immune response that provides protection from COVID-19. The study is led by Carl Fichtenbaum, MD, and Maggie Powers-Fletcher, PhD, both of the UC College of Medicine Division of Infectious Diseases.
Other coverage:
Impact Lives Here
The University of Cincinnati is leading public urban universities into a new era of innovation and impact. Our faculty, staff and students are saving lives, changing outcomes and bending the future in our city's direction. Next Lives Here.
Stay up on all UC's COVID-19 stories, read more #UCtheGood content, or take a UC virtual visit and begin picturing yourself at an institution that inspires incredible stories.
Related Stories
UC discovery points to new approach for treating diabetes — no insulin required
November 19, 2026
University of Cincinnati researchers identified a previously unknown insulin-independent pathway for glucose uptake in skeletal muscle, a discovery that could guide future treatments for diabetes, insulin resistance and high blood sugar.
Certain saturated fats may turn a ketogenic diet inflammatory
November 19, 2026
Medical News Today and MSN highlighted a University of Cincinnati Cancer Center study led by Director David Gius, MD, PhD, that found a ketogenic diet high in long-chain saturated fatty acids can increase inflammation.
Why so much hype around the new Grand Theft Auto?
November 19, 2026
UC experts from DAAP's game and animation program to a doctor at the Lindner Center of HOPE discuss the pros and cons surrounding the upcoming billion-dollar game Grand Theft Auto VI.